Bristol Myers Squibb & Eli Lilly and Company
11 shared events · Importance 4 · Last updated Aug 18, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
Bristol Myers Squibb: Bristol Myers Squibb>>>'s immunotherapies Opdivo and Yervoy are mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.
Eli Lilly and Company: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Business
Bristol Myers Squibb: Bristol Myers Squibb is the primary investor, committing $2.3 billion to build a new manufacturing campus in United States — Houston. This investment is part of its $40 billion U.S. expansion plan and is expected to enhance its manufacturing capabilities and support future drug production.
Eli Lilly and Company: Eli Lilly is mentioned as another pharmaceutical company investing in the same Generation Park area, with a $6.5 billion plant. This highlights the region's growing life sciences cluster but is not directly impacted by BMS's announcement.
Aug 10, 2026 · 20 articles
Tech
Bristol Myers Squibb: Bristol Myers Squibb is a consortium member. The publication may influence its approach to cognitive endpoints in neurodegenerative disease trials.
Eli Lilly and Company: Eli Lilly is a consortium member. The study's results could support its use of multimodal home-based assessments in CNS trials.
Aug 18, 2026 · 6 articles
Regulatory
Bristol Myers Squibb: Bristol Myers Squibb supported Gilead's appeal, gaining from the precedent that reduces innovation-related legal risks.
Eli Lilly and Company: Eli Lilly supported Gilead's appeal, benefiting from the ruling that protects drugmakers from duty-to-innovate claims.
Aug 03, 2026 · 6 articles
Business
Bristol Myers Squibb: Cited as a recent acquirer of radiopharmaceutical assets, part of the broader M&A trend in the industry.
Eli Lilly and Company: Cited among big pharma buyers of radiopharmaceutical assets from 2023 to 2025, reflecting the sector consolidation backdrop to this deal.
Sep 21, 2026 · 6 articles
Business
Bristol Myers Squibb: Bristol Myers Squibb originally licensed bempikibart to Q32 Bio; no direct impact from this event.
Eli Lilly and Company: Eli Lilly's Olumiant is a competitor JAK inhibitor for alopecia areata; positive bempikibart data may increase competition.
Jul 13, 2026 · 6 articles
Business
Bristol Myers Squibb: Bristol Myers Squibb is mentioned as a prior acquirer in the sector, highlighting the trend of radiopharmaceutical consolidation.
Eli Lilly and Company: Eli Lilly is mentioned as a prior acquirer of Point Biopharma and as a former partner with Lantheus on a PSMA-directed therapeutic that was abandoned after an unfavorable trial.
Aug 03, 2026 · 7 articles
Regulatory
Bristol Myers Squibb: Bristol Myers Squibb is one of the major drugmakers that has reached pricing agreements with the Donald Trump administration to avoid the new tariffs.
Apr 02, 2026 · 23 articles
Regulatory
Bristol Myers Squibb: Bristol Myers Squibb has a presence in Hyderabad with R&D and capability centers, contributing to India — Telangana's life sciences ecosystem.
Jan 21, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Bristol Myers Squibb and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.
Open Dashboard